Skip to main content

Table 2 Univariate analysis of influence of clinical characteristics on overall survival in hepatocellular patients

From: IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway

  

OS

 

Characteristics

N

Median survival

(months)

Survival

(%)

Log-rank

Age (years)

  < 65

100

36.83

75.00%

0.282

 ≧65

117

41.42

80.34%

 

Gender

 Female

58

38.37

76.27%

0.631

 Male

159

40.49

78.48%

 

Differentiation

 Well, Moderate

117

40.69

78.45%

0.731

 Undifferentitation, Poor

100

39.26

77.23%

 

Stage

 I, II

180

42.22

82.49%

< 0.001

 III, IV

37

30.13

57.50%

 

Hepatitis B surface antigen

 Negative

106

40.33

79.25%

0.617

 Positive

111

39.08

76.58%

 

Hepatits C virus

 Negative

150

39.14

76.67%

0.489

 Positive

67

41.1

80.60%

 

Tumor Number

 Single

177

40.25

77.78%

0.926

 Multiple

40

37.17

78.38%

 

Tumor size

  < 5 cm

140

49.79

86.43%

< 0.001

 ≧5 cm

77

33.12

62.34%

 

Relapse

 -

196

41.31

81.54%

< 0.001

 +

21

28.79

45.00%

 
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us